Free Trial

Zealand Pharma A/S Q2 2024 Earnings Report

Zealand Pharma A/S logo
$75.60 -0.50 (-0.66%)
As of 03/31/2025 10:13 AM Eastern

Zealand Pharma A/S EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.61
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$4.93 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$4.43 million
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Zealand Pharma A/S Earnings Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat